

The Manager  
Company Announcements Office  
ASX Limited

## RESULTS OF ANNUAL GENERAL MEETING

**Adelaide, 28 October 2014:** In accordance with Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001, LBT Innovations Ltd (ASX: LBT) advises that the following resolutions were passed at the Annual General Meeting of the Company held 28 October 2014.

**Resolution 1. Adoption of Remuneration Report for the year ended 30 June 2014**

It was resolved that the Remuneration Report for the financial year ended 30 June 2014 be adopted.

Details of proxies received were:

For	Against	At Discretion of Proxy	Abstain	Open Unusable / No Instruction / Excluded
23,792,741	214,703	133,795	57,805	15,478,314

The resolution was decided by a show of hands.

**Resolution 2. Re-election of Stephen Mathwin as a director**

It was resolved that Stephen Mathwin be re-elected as a director of the Company.

Details of proxies received were:

For	Against	At Discretion of Proxy	Abstain	Open Unusable / No Instruction / Excluded
39,445,721	50,537	133,795	47,305	0

The resolution was decided by a show of hands.

Yours faithfully



Lusia Guthrie  
Chief Executive Officer

– ENDS –

### About LBT Innovations

LBT Innovations (LBT) is an Australian developer of clinical and diagnostic technology. Based in Adelaide, South Australia, the Company has two breakthrough products in microbiology automation: PREVI® Isola, which provides automation of culture plate streaking, and APAS®, a breakthrough in automated culture plate imaging, interpretation and reporting. LBT also has a third product in development, Woundvue™, a proposed automation solution to assist in the management of chronic wounds.

LBT has an exclusive global licence agreement with French diagnostics company bioMérieux to manufacture and market PREVI® Isola. LBT receives ongoing royalty payments for PREVI Isola, which has been installed in clinical laboratories around the world. LBT's APAS® technology (Automated Plate Assessment System) is nearing market. Based on LBT's innovative intelligent image interpretative platform, APAS specifically addresses the automated imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a Joint Venture with Hettich AG Switzerland to drive the commercial development and global distribution of APAS instrumentation and software products.

For more information, see [www.lbtinnovations.com](http://www.lbtinnovations.com)

### CONTACTS

LBT Innovations	Media Relations
Lusia Guthrie CEO & Managing Director Tel: +61 (0)8 8227 1555 E: <a href="mailto:info@lbtinnovations.com">info@lbtinnovations.com</a>	Rudi Michelson Monsoon Communications Tel: +61 (0)3 9620 3333 E: <a href="mailto:rudim@monsoon.com.au">rudim@monsoon.com.au</a>